- HealthCap and Medicxi co-lead, joined by Forbion and Gimv
- Financing to develop emactuzumab to improve the lives of patients with tenosynovial giant cell tumours
Dublin, Ireland, November 19, 2020 –SynOx Therapeutics Ltd (“SynOx”), a clinical stage biopharmaceutical company, announces today the closing of a €37 million Series A financing co-led by HealthCap and Medicxi and joined by investors Forbion and Gimv.
SynOx, a spin out of Celleron Therapeutics Ltd (“Celleron”), secured exclusive world-wide rights for the clinical development, manufacturing and commercialization of emactuzumab under a licence agreement with Roche. The financing will enable SynOx to continue the development of emactuzumab, for the treatment of diffuse tenosynovial giant cell tumours (“TGCT”), also known as pigmented villonodular synovitis (”PVNS”), and other indications.